Helen Merritt, MD
Ophthalmic Plastic and Reconstructive Surgery · Dallas, TXNPI 1790075927
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,187 of the $4,207 with a category attached, or 75.8%. Amgen accounts for 69.1% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2024 at $1,562 and has fallen 53.2% since, to $731 in 2025.
Across 85 payments — averaging $49.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$3K
- Merz Pharmaceuticals, LLC$320
- Eyevance Pharmaceuticals LLC$199
- Edwards Lifesciences$133
- Bausch & Lomb Americas Inc.$125
- Bausch & Lomb, A Division Of Bausch Health US, LLC$88
- plus $434 from 10 others
What the payments were for
- Consulting fees$1,00024%
- Food & beverage$3,18776%
- Gifts$190%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 49 | $2,908 |
| Merz Pharmaceuticals, LLC | 11 | $320 |
| Eyevance Pharmaceuticals LLC | 4 | $199 |
| Edwards Lifesciences | 3 | $133 |
| Bausch & Lomb Americas Inc. | 1 | $125 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $88 |
| Atricure, Inc. | 1 | $88 |
| Halozyme Inc | 3 | $79 |
| Tarsus Pharmaceuticals, Inc. | 3 | $66 |
| Merz North America, Inc. | 2 | $60 |
| Shire North American Group Inc | 2 | $47 |
| Biotissue Holdings Inc. | 1 | $28 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Omeros Corporation | 1 | $19 |
| Teleflex LLC | 1 | $15 |
| Conetic Solutions, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TEPEZZA$2,025
- Zerviate$147
- IC-8 Apthera IOL$125
- enVista MX60 IOL$125
How this compares
$4,207 in reported general payments places this provider in the 65th percentile of 36 ophthalmic plastic and reconstructive surgery providers in Texas.
See all ophthalmic plastic and reconstructive surgery providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 258 | $3,040 |
| Prednisolone Acetate | 58 | $1,675 |
| Fluticasone Propionate | 12 | $185 |
| Methylprednisolone | 20 | $103 |
Paid to pharmacies, not to this prescriber.
Other ophthalmic plastic and reconstructive surgery in Dallas
- Margaret PfeifferDallas$4K
- Jorge CoronaDallas$3K
- James MerrittDallas$3K
- Meredith AbbottDallas$3K
- Kamel ItaniDallas$2K
- Phillip TenzelDallas$937
- Pooja ParikhDallas$534
- Vikram DurairajAustin$379K
- David GayDripping Springs$93K
- Richard AllenAustin$32K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.